07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Cellegy, ProStrakan deal

PSK agreed to acquire worldwide rights to three CLGY products on a royalty- and milestone-free basis for $9 million in cash. The deal, which is expected to close by the end of November, includes Tostrex...
07:00 , Oct 2, 2006 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1H06 oper loss 7/11/06 Ecopia (TSX:EIA) By 21% to 27 $3.9 0.5 5/31/06 $3.7 (A) Halts non-core activities to focus on ECO-460, in...
01:01 , Sep 28, 2006 |  BC Extra  |  Company News

ProStrakan in Novartis, Cellegy deals

ProStrakan (LSE:PSK) granted Novartis (NVS; SWX:NOVN) an exclusive worldwide license to a patent estate that allows NVS to research, develop and commercialize its preclinical MAbs against an undisclosed PSK target to treat bone-related diseases. PSK...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Company News

Sterilox management update

Sterilox Technologies Inc. , Radnor, Penn.   Business: Dermatology, Agbio/Environmental   Hired: Gregory Bosch as president and CEO, formerly VP and general manager of the BioSurgery division at Baxter International Inc. ; and Keith Goldan...
08:00 , Nov 24, 2004 |  BC Extra  |  Company News

Sterilox names Goldan CFO

Biocide and dermatology company Sterilox (Radnor, Penn.) hired Keith Goldan as CFO. Previously, Goldan was VP and CFO of Biosyn (Huntingdon Valley, Penn.). Last month, Sterilox hired Gregory Bosch as president and CEO. Bosch was...
07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Cellegy, Biosyn deal

CLGY said it will acquire Biosyn for 2.5 million shares, valuing Biosyn at $10.6 million based on CLGY's Oct. 7 close of $4.25. CLGY also will pay $3.3 million in cash to cover certain Biosyn...
07:00 , Oct 8, 2004 |  BC Extra  |  Company News

Cellegy acquiring Biosyn

CLGY said it will acquire Biosyn for 2.5 million CLGY shares, valuing Biosyn at $10.6 million based on CLGY's Thursday close of $4.25. CLGY also will pay $3.3 million in cash to cover certain Biosyn...
07:00 , May 31, 2004 |  BioCentury  |  Product Development

Antifungal pipeline

Antifungal pipeline Company Product Status Indication Target Description Barrier Zimycan Under review in EU Candida-associated diaper dermatitits P450 sterol C-14 alpha demethylase Miconazole cream Hyphanox Ph III Vaginal cadidiasis P450 sterol C-14 alpha demethylase Oral...
07:00 , May 24, 2004 |  BC Week In Review  |  Clinical News

C31G: Phase III started

Biosyn began a double-blind, placebo-controlled Phase III trial in 2,200 women in Ghana who are at risk of HIV infection. The primary endpoint is a significant reduction in seroconversion rates in the C31G group vs....
08:00 , Nov 24, 2003 |  BC Week In Review  |  Clinical News

1 regulatory update

The FDA granted Fast Track designation to Biosyn's C31G vaginal gel to reduce HIV transmission. C31G is entering Phase III trials. Biosyn Inc. , Huntingdon Valley, Penn.   Product: 1.0% C31G intra-vaginal gel   Business:...